# A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

> **NCT00324194** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 25 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** MGCD0103

## Key facts

- **NCT ID:** NCT00324194
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324194, "A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00324194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*